Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca has published the notice and shareholders’ circular for its 2026 Annual General Meeting, which will be digitally enabled and held on 9 April 2026 at 14:30 BST. The documents, including the proxy form and updated 2020 Performance Share Plan rules, have been filed with the UK National Storage Mechanism and are available on the company’s website.
Shareholders will vote on routine but strategically important items, including approval of 2025 accounts and dividends, re-election of directors, auditor appointment, and multiple capital authorities such as share allotment, pre-emption disapplication and share buybacks. The notice also sets record dates and participation rules for holders across the UK, US and Swedish markets, underscoring AstraZeneca’s broad international investor base and governance framework.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company specialising in the discovery, development and commercialisation of prescription medicines. Headquartered in Cambridge, UK, it focuses on Oncology, Rare Diseases and BioPharmaceuticals, including cardiovascular, renal, metabolism, respiratory and immunology therapies, with products sold in more than 125 countries.
Average Trading Volume: 2,692,920
Technical Sentiment Signal: Buy
Current Market Cap: £224B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.